These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 23559676)

  • 1. The skeletal consequences of growth hormone therapy in dialyzed children: a randomized trial.
    Bacchetta J; Wesseling-Perry K; Kuizon B; Pereira RC; Gales B; Wang HJ; Elashoff R; Salusky IB
    Clin J Am Soc Nephrol; 2013 May; 8(5):824-32. PubMed ID: 23559676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism.
    Wesseling-Perry K; Pereira RC; Sahney S; Gales B; Wang HJ; Elashoff R; Jüppner H; Salusky IB
    Kidney Int; 2011 Jan; 79(1):112-9. PubMed ID: 20861820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Correlation between osteocalcin and bone histomorphometry in children with chronic renal failure].
    Weglarska J; Ziółkowska H; Pańczyk-Tomaszewska M; Sieniawska M
    Pediatr Pol; 1995 Dec; 70(12):1011-5. PubMed ID: 8649939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone mineral density, bone metabolism and body composition of children with chronic renal failure, with and without growth hormone treatment.
    Boot AM; Nauta J; de Jong MC; Groothoff JW; Lilien MR; van Wijk JA; Kist-van Holthe JE; Hokken-Koelega AC; Pols HA; de Muinck Keizer-Schrama SM
    Clin Endocrinol (Oxf); 1998 Nov; 49(5):665-72. PubMed ID: 10197084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 25-hydroxyvitamin D levels and bone histomorphometry in hemodialysis renal osteodystrophy.
    Coen G; Mantella D; Manni M; Balducci A; Nofroni I; Sardella D; Ballanti P; Bonucci E
    Kidney Int; 2005 Oct; 68(4):1840-8. PubMed ID: 16164662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Value of the new bone classification system in pediatric renal osteodystrophy.
    Bakkaloglu SA; Wesseling-Perry K; Pereira RC; Gales B; Wang HJ; Elashoff RM; Salusky IB
    Clin J Am Soc Nephrol; 2010 Oct; 5(10):1860-6. PubMed ID: 20634327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum markers of low-turnover bone disease in Mexican children with chronic kidney disease undergoing dialysis.
    Avila-Díaz M; Matos M; García-López E; Prado MD; Castro-Vázquez F; Ventura MD; González E; Amato D; Paniagua R
    Perit Dial Int; 2006; 26(1):78-84. PubMed ID: 16538879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New worldwide trends in presentation of renal osteodystrophy and its relationship to parathyroid hormone levels.
    Gal-Moscovici A; Popovtzer MM
    Clin Nephrol; 2005 Apr; 63(4):284-9. PubMed ID: 15847255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnosis of renal osteodystrophy: when and how to use biochemical markers and non-invasive methods; when bone biopsy is needed.
    Ferreira MA
    Nephrol Dial Transplant; 2000; 15 Suppl 5():8-14. PubMed ID: 11073268
    [No Abstract]   [Full Text] [Related]  

  • 10. Racial-ethnic differences in chronic kidney disease-mineral bone disorder in youth on dialysis.
    Laster M; Soohoo M; Streja E; Elashoff R; Jernigan S; Langman CB; Norris KC; Salusky IB; Kalantar-Zadeh K
    Pediatr Nephrol; 2019 Jan; 34(1):107-115. PubMed ID: 30267239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Variation of bone acquisition during growth hormone treatment in children can be explained by proteomic biomarkers, bone formation markers, body composition and nutritional factors.
    Swolin-Eide D; Andersson B; Hellgren G; Magnusson P; Albertsson-Wikland K
    Bone; 2018 Nov; 116():144-153. PubMed ID: 30071306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Calcitriol oral pulse therapy in children with renal osteodystrophy.
    Cano F; Delucchi A; Wolff E; Rodriguez E; Fuentes A
    Pediatr Nephrol; 1995 Oct; 9(5):606-8. PubMed ID: 8580020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Similar predictive value of bone turnover using first- and second-generation immunometric PTH assays in pediatric patients treated with peritoneal dialysis.
    Salusky IB; Goodman WG; Kuizon BD; Lavigne JR; Zahranik RJ; Gales B; Wang HJ; Elashoff RM; Jüppner H
    Kidney Int; 2003 May; 63(5):1801-8. PubMed ID: 12675856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growth hormone and the skeleton in pediatric renal allograft recipients.
    Sanchez CP; Kuizon BD; Goodman WG; Gales B; Ettenger RB; Boechat MI; Wang Y; Elashoff R; Salusky IB
    Pediatr Nephrol; 2002 May; 17(5):322-8. PubMed ID: 12042887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conversion from Intravenous Vitamin D Analogs to Oral Calcitriol in Patients Receiving Maintenance Hemodialysis.
    Thadhani RI; Rosen S; Ofsthun NJ; Usvyat LA; Dalrymple LS; Maddux FW; Hymes JL
    Clin J Am Soc Nephrol; 2020 Mar; 15(3):384-391. PubMed ID: 32111702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between plasma fibroblast growth factor-23 concentration and bone mineralization in children with renal failure on peritoneal dialysis.
    Wesseling-Perry K; Pereira RC; Wang H; Elashoff RM; Sahney S; Gales B; Jüppner H; Salusky IB
    J Clin Endocrinol Metab; 2009 Feb; 94(2):511-7. PubMed ID: 19050056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy.
    Goodman WG; Ramirez JA; Belin TR; Chon Y; Gales B; Segre GV; Salusky IB
    Kidney Int; 1994 Oct; 46(4):1160-6. PubMed ID: 7861712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term effects of growth hormone treatment on growth and puberty in patients with chronic renal insufficiency.
    Hokken-Koelega A; Mulder P; De Jong R; Lilien M; Donckerwolcke R; Groothof J
    Pediatr Nephrol; 2000 Jul; 14(7):701-6. PubMed ID: 10912546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of 12 months of recombinant growth hormone therapy on parameters of bone metabolism and bone mineral density in patients on chronic hemodialysis.
    Kotzmann H; Riedl M; Pietschmann P; Schmidt A; Schuster E; Kreuzer S; Kainberger F; Frisch H; Geyer G; Hörl WH; Mayer G; Luger A
    J Nephrol; 2004; 17(1):87-94. PubMed ID: 15151263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in bone matrix mineralization after growth hormone treatment in children and adolescents with chronic kidney failure treated by dialysis: a paired biopsy study.
    Nawrot-Wawrzyniak K; Misof BM; Roschger P; Pańczyk-Tomaszewska M; Ziółkowska H; Klaushofer K; Fratzl-Zelman N
    Am J Kidney Dis; 2013 May; 61(5):767-77. PubMed ID: 23465957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.